Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Avutometinib, avutometinib (VS-6766), avutometinib
avutometinib and sotorasib · 3 trials · 6 indications
Confirmed overall response rate per RECIST 1.1
Confirmed overall response rate per RECIST 1.1
Confirmed overall response rate per RECIST 1.1
Confirmed overall response rate per RECIST 1.1
Assessment of Dose-limiting toxicities (DLTs)
Confirmed overall response rate per RECIST 1.1
Assessment of Dose-limiting toxicities (DLTs)
Confirmed overall response rate per RECIST 1.1
| Arm | Type | Description |
|---|---|---|
| Arm 1: avutometinib (VS-6766) monotherapy | EXPERIMENTAL | in patients with NSCLC KRAS-G12V tumor |
| Arm 2: avutometinib (VS-6766) in combination with defactinib | EXPERIMENTAL | in patients with a NSCLC KRAS-G12V tumor |
| Arm 3: avutometinib (VS-6766) in combination with defactinib | EXPERIMENTAL | in patients with a NSCLC KRAS-other (non-G12V) tumor |
| Arm 4: avutometinib (VS-6766) in combination with defactinib | EXPERIMENTAL | in patients with a NSCLC BRAF-V600E tumor |
| Arm 5:avutometinib (VS-6766) in combination with defactinib | EXPERIMENTAL | in patients with a NSCLC BRAF-non-V600E tumor |
| avutometinib(VS-6766)+adagrasib | EXPERIMENTAL | To determine the recommended phase 2 dose (RP2D) for VS-6766 in combination with adagrasib in G12C inhibitor exposed patients |
| avutometinib (VS-6766)+adagrasib RP2D | EXPERIMENTAL | To determine the efficacy of the RP2D identified from Part A in G12C inhibitor exposed patients |
| avutometinib (VS-6766)+sotorasib | EXPERIMENTAL | To determine the recommended phase 2 dose (RP2D) for avutometinib (VS 6766) in combination with sotorasib in KRAS G12C inhibitor naïve and exposed patients |
| avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor naïve | EXPERIMENTAL | To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients |
| avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor exposed | EXPERIMENTAL | To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients |
| avutometinib (VS-6766)+sotorasib+defactinib | EXPERIMENTAL | To determine the recommended phase 2 dose (RP2D) for avutometinib (VS-6766) in combination with sotorasib and defactinib in KRAS G12C inhibitor exposed patients |
| avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor naive | EXPERIMENTAL | To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients |
| avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor exposed | EXPERIMENTAL | To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients |
| Name | Type | Description |
|---|---|---|
| avutometinib (VS-6766) | DRUG | Monotherapy |
| avutometinib (VS-6766) and Defactinib | DRUG | Combination therapy |
| avutometinib (VS-6766) and adagrasib | DRUG | The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion |
| avutometinib and sotorasib | DRUG | The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion |
| avutometinib and sotorasib and defactinib | DRUG | The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion |
Inclusion Criteria: * Male or female subjects ≥ 18 years of age * Histologic or cytologic evidence of NSCLC * Known KRAS or BRAF mutation * The subject must have received appropriate prior therapy * Measurable disease according to RECIST 1.1 * An Eastern Cooperative Group (ECOG) performance status ...
Top 20 of 84 competitors
Avutometinib is an investigational small molecule being studied for the treatment of several cancers, including low grade serous ovarian cancer, glioblastoma multiforme (GBM), endometrioid cancer, and non small cell lung cancer. It is currently in Phase 2 clinical development for these indications.
Avutometinib is a kinase inhibitor, as indicated by its '-tinib' suffix. It is being studied both as a monotherapy and in combination with other agents, such as defactinib, for the treatment of various solid tumors.
Avutometinib is being developed by Verastem, Inc., a biopharmaceutical company. Verastem is listed on the stock exchange under the ticker symbol VSTM.
Avutometinib is currently in Phase 2 clinical trials. It has received Breakthrough Therapy designation and Orphan Drug designation from the FDA for certain indications, reflecting its potential in treating serious conditions.
Avutometinib is being evaluated in several clinical trials, including NCT04625270, a Phase 2 study in recurrent low-grade serous ovarian cancer; NCT05798507, an early Phase 1 study in glioblastoma; NCT06630260, a Phase 1 study in malignant brain tumors; and NCT07747506, a continued access study in low-grade serous ovarian cancer.
Yes, Avutometinib is also known as VS-6766. In clinical trials, it is often referred to as avutometinib (VS-6766), particularly when studied in combination with defactinib for conditions like low-grade serous ovarian cancer and glioblastoma.